Search & Analyze

Aurobindo Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.aurobindo.com BSE: 524804NSE: AUROPHARMA

₹1,658.00BSE1.18%

07 Sep, 4:01 PM

₹1,658.00

₹95.40K Cr

25.70

2.45

9.93%

₹1,666.60

₹1,638.65

₹1,706.70

₹1,034.85

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
Aurobindo Pharma Ltd. AUROPHARMA	1,658.00	25.70	95,397.65	0.24	1,032.03	25.22%	9,150.35	16.30%	12.76

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	7,580.15	7,567.02	7,796.07	7,978.52	8,382.12	7,868.14	8,285.70	8,645.90	8,853.34	9,150.35
Expenses	5,907.34	5,947.45	6,229.93	6,400.54	6,590.20	6,265.11	6,607.60	6,872.56	7,100.56	7,269.29
	1,672.81	1,619.57	1,566.14	1,577.98	1,791.92	1,603.03	1,678.10	1,773.34	1,752.78	1,881.06
	22.07%	21.40%	20.09%	19.78%	21.38%	20.37%	20.25%	20.51%	19.80%	20.56%
	13.51	220.93	136.00	157.29	134.81	105.30	120.59	122.31	117.04	224.05
Interest	89.43	111.04	112.70	118.48	115.02	97.75	95.24	92.77	98.21	101.66
	354.33	404.18	382.28	418.53	444.43	405.70	429.19	464.73	478.57	486.82
	1,229.90	1,323.89	1,207.46	1,199.85	1,335.09	1,206.80	1,275.92	1,338.52	1,290.61	1,515.09
	26.23%	30.64%	32.34%	29.53%	32.38%	31.70%	33.53%	32.03%	28.65%	31.88%
	908.75	919.22	817.38	845.81	903.47	824.75	848.45	910.29	921.26	1,032.56
	15.51	15.69	14.07	14.56	15.56	14.20	14.61	15.67	15.86	17.95

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	47,811.72	50,860.13	59,784.10	63,558.91	69,519.14
	23,455.49	24,855.38	29,001.87	31,723.73	33,653.08
EXPENDITURE :
Increase/Decrease in Stock	816.68	-409.68	-946.17	-597.63	-294.81
Raw Material Consumed	8,422.23	10,600.16	12,294.95	12,269.52	12,309.21
Power & Fuel Cost	626.86	842.63	826.03	1,012.25	1,117.61
Employee Cost	3,450.92	3,522.25	3,922.94	4,475.62	5,190.17
Other Manufacturing Expenses	2,502.98	2,810.03	3,191.71	3,556.25	3,760.09
General and Administration Expenses	1,335.03	1,386.66	1,483.77	1,551.60	1,763.42
Selling and Distribution Expenses	1,496.67	1,685.76	1,684.72	2,185.06	2,254.93
Miscellaneous Expenses	419.58	698.93	700.92	688.27	735.13
	19,070.95	21,136.74	23,158.87	25,140.94	26,835.75
Operating Profit (Excl OI)	4,384.54	3,718.64	5,843.00	6,582.79	6,817.33
	322.58	290.59	557.38	621.85	520.49
	4,707.12	4,009.23	6,400.38	7,204.64	7,337.82
Interest	48.64	140.48	289.71	457.24	383.97
PBDT	4,658.48	3,868.75	6,110.67	6,747.40	6,953.85
	1,126.52	1,244.58	1,521.66	1,649.42	1,778.19
Profit Before Taxation & Exceptional Items	3,531.96	2,624.17	4,589.01	5,097.98	5,175.66
Exceptional Income / Expenses	-127.97		-191.86		-65.33
	3,372.74	2,612.50	4,379.99	5,066.29	5,111.85
Provision for Tax	725.63	684.85	1,211.02	1,582.72	1,608.88
	2,647.11	1,927.65	3,168.97	3,483.57	3,502.97
Extra items				0.00	0.00
Minority Interest	1.04	-0.15	4.00	2.31	1.78
Consolidated Net Profit	2,648.15	1,927.50	3,172.97	3,485.88	3,504.75
Profit Balance B/F	20,136.76	22,518.99	23,910.41	26,801.42	30,221.65
Appropriations	22,784.91	24,446.49	27,083.38	30,287.30	33,726.40
Equity Dividend %	900.00%	300.00%	450.00%		400.00%
	45.20	32.90	54.16	60.02	60.34
Adjusted EPS	45.20	32.90	54.16	60.02	60.34

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	58.59	58.59	58.59	58.08	58.08
Total Reserves	24,517.39	26,781.26	29,784.21	32,595.24	37,832.89
Reserve excluding Revaluation Reserve	24,517.39	26,781.26	29,784.21	32,595.24	37,832.89
Revaluation reserve	0.00
	24,575.98	26,839.85	29,842.80	32,653.32	37,890.97
Minority Interest	-1.93	12.00	8.00	-6.39	-8.16
Secured Loans	249.21	618.96	2,134.90	1,159.38	798.20
Unsecured Loans				402.27	4.55
Deferred Tax Assets / Liabilities	122.37	-287.88	-856.08	-989.69	-1,177.59
Other Long Term Liabilities	359.73	363.07	304.42	307.85	1,071.17
Long Term Provisions	171.79	172.72	225.70	282.93	400.41
Total Non-Current Liabilities	903.10	866.87	1,808.94	1,162.74	1,096.74
Trade Payables	2,703.05	3,871.31	4,454.16	4,188.85	5,567.27
Other Current Liabilities	3,106.51	2,979.91	3,161.05	4,462.78	5,828.46
Short Term Borrowings	2,117.83	4,230.43	4,078.12	5,470.22	6,079.64
Short Term Provisions	228.59	412.13	505.80	560.49	563.64
Total Current Liabilities	8,155.98	11,493.78	12,199.13	14,682.34	18,039.01
Total Liabilities	33,633.13	39,212.50	43,858.87	48,492.01	57,018.56
Gross Block	15,943.09	18,593.32	23,447.77	24,462.96	29,251.05
Less: Accumulated Depreciation	5,411.00	7,569.63	8,952.24	9,668.77	11,844.47
Less: Impairment of Assets			2.74
Net Block	10,532.09	11,023.69	14,492.79	14,794.19	17,406.58
Capital Work in Progress	2,937.56	4,496.40	2,739.39	3,266.00	3,008.83
Non Current Investments	618.30	391.74	321.65	251.70	303.88
Long Term Investment	618.30	391.74	321.65	251.70	303.88
Long Term Loans & Advances	575.33	794.00	714.55	973.42	971.58
Other Non Current Assets	37.52	67.39	255.53	410.28	414.21
Total Non-Current Assets	15,510.44	17,666.83	19,653.24	21,329.55	24,309.81
Currents Investments	378.85	151.00	50.58	0.01	747.24
Inventories	7,553.85	8,511.23	9,808.23	10,543.72	12,052.94
Sundry Debtors	4,012.26	4,466.38	4,816.74	5,745.93	7,094.37
Cash and Bank	4,190.01	6,084.20	6,278.30	8,235.49	9,870.29
Other Current Assets	393.95	554.71	519.45	654.00	398.75
Short Term Loans and Advances	1,514.67	1,692.39	2,298.62	1,983.31	2,545.16
Total Current Assets	18,043.59	21,459.91	23,771.92	27,162.46	32,708.75
Net Current Assets (Including Current Investments)	9,887.61	9,966.13	11,572.79	12,480.12	14,669.74
Total Assets	33,633.13	39,212.50	43,858.87	48,492.01	57,018.56
Contingent Liabilities	157.74	158.53	311.34	1,290.26	1,358.37
Total Debt	2,372.77	4,861.52	6,315.22	7,941.68	7,676.20
	419.46	458.10	509.35	562.21	652.39
Adjusted Book Value	419.46	458.10	509.35	562.21	652.39

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	3,372.74	2,612.50	4,379.99	5,066.29	5,111.85
Adjustment	1,344.13	1,586.47	1,496.24	1,834.16	2,082.62
Changes In working Capital	1,557.80	-1,094.98	-1,675.07	-1,244.48	163.93
Cash Flow after changes in Working Capital	6,274.67	3,103.99	4,201.16	5,655.97	7,358.40
Cash Flow from Operating Activities	5,016.48	2,386.75	2,434.52	3,924.62	5,526.37
Cash Flow from Investing Activities	-3,211.56	-3,977.75	-4,255.95	-1,875.80	-3,458.61
Cash Flow from Financing Activitie	-2,969.27	1,814.41	800.42	119.78	-1,269.15
Net Cash Inflow / Outflow	-1,164.35	223.41	-1,021.01	2,168.60	798.61
Opening Cash & Cash Equivalents	5,329.91	4,162.51	4,392.27	3,385.43	5,563.79
Cash & Cash Equivalent of Subsidiaries under liquidations	-3.25	6.41		0.66	0.18
Effect of Foreign Exchange Fluctuations	0.20	-0.06	14.17	9.10	828.82
Closing Cash & Cash Equivalent	4,162.51	4,392.27	3,385.43	5,563.79	7,191.40

Ratios

Valuation

25.70

2.45

11.99

2.75

64.52

676.49

Profitability

9.93

12.76

6.64

9.81

5.04

Leverage & Liquidity

0.20

1.81

14.31

Returns

0.24

1.32

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	51.80	51.82	51.82	51.82	51.82	51.82	51.82	51.82	51.88
	41.50	41.72	41.49	41.56	41.30	41.81	41.63	41.11	41.48
	6.70	6.46	6.69	6.61	6.87	6.38	6.56	7.08	6.64
	48.20	48.18	48.18	48.18	48.18	48.18	48.18	48.18	48.12
No. of Shareholders	2,38,622	2,48,488	2,57,962	2,69,323	2,72,208	2,47,662	2,36,859	2,41,298	2,39,073

Corporate Actions

Showing: All

Date	Type	Details
2026-07-29	AGM
2026-07-27	Board Meeting	Quarterly Results
2026-05-12	Board Meeting	Audited Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Aurobindo Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

11 members across the board and senior leadership

Mangalam Ramasubramanian Kumar

Chairman

₹37.00 L

Mar '26

K Nityananda Reddy

Vice Chairman & Managing Director

₹5.47 Cr

Mar '26

M Madan Mohan Reddy

Whole Time Director

₹6.98 Cr

Mar '26

Santanu Mukherjee

Non Executive Independent Director

₹41.00 L

Mar '26

Girish Paman Vanvari

Non Executive Independent Director

₹42.00 L

Mar '26

Punita Kumar Sinha

Non Executive Independent Director

₹6.80 L

Mar '26

Deepali Pant Joshi

Non Executive Independent Director

₹36.00 L

Mar '25

P Sarath Chandra Reddy

Non Independent & Non Executive Director

₹8.00 L

Mar '26

PV Ramprasad Reddy

Promoter & Non-Executive Director

₹5.00 L

Mar '26

Satakarni Makkapati

Non Independent & Non Executive Director

₹9.00 L

Mar '26

B Adi Reddy

Company Secretary & Compliance Officer

—

AUROPHARMA Latest News

News

10 of 10 articles

EQUITY2 Sept 2026 · 14:35

Aurobindo Pharma moves up as its arm incorporates wholly owned subsidiary

The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

EQUITY1 Sept 2026 · 14:12

Aurobindo Pharma informs about disclosure

COMPANY1 Sept 2026 · 13:05

Aurobindo Pharma’s arm incorporates wholly owned subsidiary

The object of incorporation of this wholly owned subsidiary is to undertake manufacturing and marketing operations in India and foreign countries

EQUITY31 Aug 2026 · 11:20

Aurobindo Pharma gains as its arm launches generic equivalent of Advair Diskus in US market

Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease

EQUITY31 Aug 2026 · 11:10

Aurobindo Pharma informs about press release

COMPANY31 Aug 2026 · 10:58

Aurobindo Pharma’s arm launches generic equivalent of Advair Diskus in US market

Advair Diskus in combination therapy is indicated for the treatment of asthma and chronic obstructive pulmonary disease

COMPANY28 Aug 2026 · 17:27

USFDA completes inspection at Aurobindo Pharma’s arm’s Andhra Pradesh facility

The inspection concluded with three observations, which are procedural in nature

COMPANY24 Aug 2026 · 15:41

Aurobindo Pharma’s arm receives four observations from USFDA

The USFDA conducted a routine inspection at Lannett Company LLC from August 17 to August 21, 2026

COMPANY24 Aug 2026 · 09:28

USFDA concludes inspection at Aurobindo Pharma’s AuroPeptides with one observation

The USFDA conducted inspection at AuroPeptides from August 17 to 21, 2026

EQUITY17 Aug 2026 · 09:00

Aurobindo Pharma informs about clarification

AUROPHARMA

₹1,658.00

+1.18%